Laddar...
Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
The treatment of cystic fibrosis (CF) patients homozygous for the F508del mutation with Orkambi(®), a combination of a corrector (lumacaftor) and a potentiator (ivacaftor) of the mutated CFTR protein, resulted in some amelioration of the respiratory function. However, a great variability in the clin...
Sparad:
I publikationen: | Int J Mol Sci |
---|---|
Huvudupphovsmän: | , , , , , , , , , , , |
Materialtyp: | Artigo |
Språk: | Inglês |
Publicerad: |
MDPI
2020
|
Ämnen: | |
Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7177453/ https://ncbi.nlm.nih.gov/pubmed/32244302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21072398 |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|